Automatic Detection of ON/OFF states in Parkinson Disease Patients Using Wearable Sensor Technology (S3.007)
Abstract
Objective:
To detect self-reported ON and OFF states in Parkinson Disease (PD) patients from wearable sensor technology.
Background:
Reliably detecting ON/OFF states is important for monitoring PD treatment and progression. Currently, subjective patient diaries capture this information. We investigate if detection of motor signs of ON/OFF states can be achieved by using kinematic measurements from wearable sensor technology combined with a machine learning (ML) pipeline.
Design/Methods:
Twenty-five PD subjects (19 males, 69±7 years) taking levodopa performed 10-meter Instrumented Stand and Walk (ISAW) tests in their ON and OFF states while wearing Ambulatory Parkinson Disease Monitoring (APDM) sensors on their sternum, wrists, lumbar and lower extremities. A neurologist scored each ISAW according to the MDS-UPDRS-III. We analyzed 98 kinematic features for significance to neurologist total motor score and ON/OFF using both statistical (repeated-measures ANOVA, step-wise mixed-model regression, likelihood-ratio test, ridge regression) and ML methods.
Results:
Twenty-two features significantly differed between patient reported ON/OFF states, with the most significant being trunk transverse range-of-motion (RofM), arm RofM, mid-swing elevation, stride length, turn velocity, steps in turn and toe out angles. Estimates from regression model showed average difference of 14 points between OFF/ON states in total UPDRS score and 9 points when adjusted for 5 significant features for individual baseline (mean trunk transverse RofM, right arm RofM, and toe out angle having highest effect; coeff. −8.67, −5.25, −3.36 respectively). Several approaches were employed for predicting ON/OFF states based on these features: direct binary classification (acc=0.56), regression to total UPDRS score (acc=0.76), regression to PIGD sub-score (acc=0.64), and classification of ON-OFF/OFF-ON transitions using feature differences (Naïve Bayes: acc=0.74, AUC=0.78; Random Forest: acc=0.76, AUC=0.90).
Conclusions:
Wearable sensor technology holds promise for detecting ON/OFF states in PD patients using an augmented ML approach. This could be particularly useful for monitoring response to therapy in an outpatient setting.
Disclosure: Dr. Anand has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with IBM. Dr. Bilal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with IBM. Dr. Ramos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Naylor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Demauele has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc., Biogen. Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc. Dr. Amato has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Wacnik has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, inc. Dr. Hameed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Kangarloo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc. Dr. Ho has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Erb has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer, Inc. Dr. Karlin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc.
Information & Authors
Information
Published In
Neurology®
Volume 90 • Number 15_supplement • April 10, 2018
Copyright
© 2018.
Publication History
Published online: April 10, 2018
Published in print: April 10, 2018
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
View Options
View options
PDF and All Supplements
Download PDF and Supplementary MaterialLogin options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.